Juan Carlos L. G.
- Country
- Spain
- Department
- 1500: Cirugía Plástica
Research Overview
- Efficacy and Safety of Alpelisib in Pediatric and Adult Patients with PIK3CA-Mutated Lymphatic Malformations: A Randomized, Double-Blind, Placebo-Controlled Study
- Evaluation of Long-Term Safety and Efficacy of Alpelisib in Patients with PIK3CA-Related Overgrowth Spectrum (PROS) Following Participation in Study CBYL719F12002
- Phase 2 Evaluation of RLY-2608 in PIK3CA-Related Overgrowth Spectrum and PIK3CA Mutation-Driven Malformations in Adult and Pediatric Populations
Data & Insights
Has run more than one trial at 27 of 53 partner sites.
Specializations
Genetic Disorders
The investigator specializes in studying PIK3CA-related conditions, with particular emphasis on understanding and treating genetic mutations that lead to tissue overgrowth and malformations.
- PIK3CA-Related Overgrowth Spectrum (PROS)
- Genetic mutation analysis
- Tissue overgrowth disorders
Their research encompasses comprehensive evaluation of genetic pathways involved in tissue development and growth regulation.
Vascular Abnormalities
Focused on the treatment of lymphatic malformations, particularly those associated with specific genetic mutations. The investigator studies vascular system disorders and their molecular basis.
- Lymphatic system disorders
- Vascular malformations
- Targeted therapeutic approaches
Their work involves evaluating novel therapeutic interventions for complex vascular anomalies.
Therapeutic Development
The investigator explores the application of targeted therapies for genetic and vascular conditions, with specific interest in long-term treatment outcomes and safety profiles.
- Novel therapeutic agents
- Long-term safety assessment
- Treatment efficacy evaluation
Their research includes assessment of therapeutic responses in both adult and pediatric populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.